FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281729246> ?p ?o ?g. }

• W4281729246 abstract "Abstract Background The multidisciplinary treatment including induction chemotherapy plus conversion surgery (CS) has attracted attention as a new strategy to improve the outcome of metastatic gastric cancer (MGC). However, it is unclear which patients achieve a good response to chemotherapy and successful CS. Tumor-infiltrating immune cells (TIICs) have been reported to be both prognostic and predictive biomarkers not only in immunotherapy but also in chemotherapy in many cancer types. However, there have been no reports on the usefulness of TIICs as biomarkers in conversion surgery for MGC. The aim of the present study was to evaluate the association between the TIICs and treatment outcome for the multidisciplinary treatment in MGC. Methods We retrospectively analyzed 68 MGC patients who received docetaxel plus cisplatin plus S-1 (DCS) therapy between April 2006 and March 2019 in our institute. The number of tumor-infiltrating CD4 + , CD8 + , Foxp3 + lymphocytes, CD68 + , CD163 + macrophages in pre-treatment endoscopic biopsy samples were evaluated to investigate their predictive value for multidisciplinary treatment. Results Fifty patients underwent CS following DCS therapy (CS group), whereas 18 patients underwent DCS therapy alone (non-CS group). The median survival time (MST) of CS group was 33.3 months, which was significantly longer than the MST of 9.0 months in non-CS group ( p < 0.01). The number of CD163 + macrophages was extracted as an independent prognostic factor for overall survival in all patients. There were more cases of high infiltration of CD163 + macrophages in non-CS group than in CS group. Furthermore, in CS group, pathological responders to DCS therapy showed low infiltration of CD163 + macrophages, and high infiltration of CD8 + lymphocyte. CD163 low group showed a significant prolonged survival compared with CD163 high group in patients who underwent CS ( p = 0.02). Conclusions The pre-treatment CD163 + macrophages infiltration would be a pivotal biomarker for predicting prognosis and pathological response to multidisciplinary treatment among TIICs in MGC. Thus, for patients with low CD163 + macrophage infiltration in pre-treatment biopsy sample, diagnostic imaging should be performed frequently during chemotherapy to avoid missing the optimal timing for CS, and CS should be aggressively considered as a treatment option if curative resection is deemed feasible." @default.
• W4281729246 created "2022-06-13" @default.
• W4281729246 creator A5018007136 @default.
• W4281729246 creator A5019363829 @default.
• W4281729246 creator A5020009832 @default.
• W4281729246 creator A5024644803 @default.
• W4281729246 creator A5044136996 @default.
• W4281729246 creator A5047407485 @default.
• W4281729246 creator A5048730959 @default.
• W4281729246 creator A5049329632 @default.
• W4281729246 creator A5072194347 @default.
• W4281729246 creator A5081395068 @default.
• W4281729246 creator A5081758735 @default.
• W4281729246 creator A5084113589 @default.
• W4281729246 date "2022-06-03" @default.
• W4281729246 modified "2023-09-30" @default.
• W4281729246 title "Prognostic value of tumor-infiltrating CD163+macrophage in patients with metastatic gastric cancer undergoing multidisciplinary treatment" @default.
• W4281729246 cites W1943731099 @default.
• W4281729246 cites W1964233911 @default.
• W4281729246 cites W2015463293 @default.
• W4281729246 cites W2016967137 @default.
• W4281729246 cites W2019607817 @default.
• W4281729246 cites W2041399091 @default.
• W4281729246 cites W2067616322 @default.
• W4281729246 cites W2100439220 @default.
• W4281729246 cites W2113082145 @default.
• W4281729246 cites W2119113008 @default.
• W4281729246 cites W2120431466 @default.
• W4281729246 cites W2157612047 @default.
• W4281729246 cites W2163035374 @default.
• W4281729246 cites W2165317945 @default.
• W4281729246 cites W2195172068 @default.
• W4281729246 cites W2341289486 @default.
• W4281729246 cites W2416124421 @default.
• W4281729246 cites W2509298856 @default.
• W4281729246 cites W2522869448 @default.
• W4281729246 cites W2794325812 @default.
• W4281729246 cites W2801045207 @default.
• W4281729246 cites W2801279586 @default.
• W4281729246 cites W2851002427 @default.
• W4281729246 cites W2898415660 @default.
• W4281729246 cites W2899783716 @default.
• W4281729246 cites W2911385002 @default.
• W4281729246 cites W2969765283 @default.
• W4281729246 cites W2982058960 @default.
• W4281729246 cites W2982590838 @default.
• W4281729246 cites W3002759430 @default.
• W4281729246 cites W3021331025 @default.
• W4281729246 cites W3034913219 @default.
• W4281729246 cites W3046770314 @default.
• W4281729246 cites W3125607249 @default.
• W4281729246 cites W4246328459 @default.
• W4281729246 doi "https://doi.org/10.1186/s12885-022-09713-y" @default.
• W4281729246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35658848" @default.
• W4281729246 hasPublicationYear "2022" @default.
• W4281729246 type Work @default.
• W4281729246 citedByCount "0" @default.
• W4281729246 crossrefType "journal-article" @default.
• W4281729246 hasAuthorship W4281729246A5018007136 @default.
• W4281729246 hasAuthorship W4281729246A5019363829 @default.
• W4281729246 hasAuthorship W4281729246A5020009832 @default.
• W4281729246 hasAuthorship W4281729246A5024644803 @default.
• W4281729246 hasAuthorship W4281729246A5044136996 @default.
• W4281729246 hasAuthorship W4281729246A5047407485 @default.
• W4281729246 hasAuthorship W4281729246A5048730959 @default.
• W4281729246 hasAuthorship W4281729246A5049329632 @default.
• W4281729246 hasAuthorship W4281729246A5072194347 @default.
• W4281729246 hasAuthorship W4281729246A5081395068 @default.
• W4281729246 hasAuthorship W4281729246A5081758735 @default.
• W4281729246 hasAuthorship W4281729246A5084113589 @default.
• W4281729246 hasBestOaLocation W42817292461 @default.
• W4281729246 hasConcept C121608353 @default.
• W4281729246 hasConcept C126322002 @default.
• W4281729246 hasConcept C141071460 @default.
• W4281729246 hasConcept C143998085 @default.
• W4281729246 hasConcept C185592680 @default.
• W4281729246 hasConcept C202751555 @default.
• W4281729246 hasConcept C204232928 @default.
• W4281729246 hasConcept C2775858924 @default.
• W4281729246 hasConcept C2776460901 @default.
• W4281729246 hasConcept C2776694085 @default.
• W4281729246 hasConcept C2777701055 @default.
• W4281729246 hasConcept C2779244956 @default.
• W4281729246 hasConcept C2780140570 @default.
• W4281729246 hasConcept C55493867 @default.
• W4281729246 hasConcept C71924100 @default.
• W4281729246 hasConcept C90924648 @default.
• W4281729246 hasConceptScore W4281729246C121608353 @default.
• W4281729246 hasConceptScore W4281729246C126322002 @default.
• W4281729246 hasConceptScore W4281729246C141071460 @default.
• W4281729246 hasConceptScore W4281729246C143998085 @default.
• W4281729246 hasConceptScore W4281729246C185592680 @default.
• W4281729246 hasConceptScore W4281729246C202751555 @default.
• W4281729246 hasConceptScore W4281729246C204232928 @default.
• W4281729246 hasConceptScore W4281729246C2775858924 @default.
• W4281729246 hasConceptScore W4281729246C2776460901 @default.
• W4281729246 hasConceptScore W4281729246C2776694085 @default.
• W4281729246 hasConceptScore W4281729246C2777701055 @default.
• W4281729246 hasConceptScore W4281729246C2779244956 @default.
• W4281729246 hasConceptScore W4281729246C2780140570 @default.

• next